Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Clinical Oncology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.72.1316PMID 28441111PMCID PMC5791843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

  2016cited by this paper
• Hodgkin lymphoma: Pathology and biology.

  2016cited by this paper
• Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

  2016cited by this paper
• Treatment of early-stage Hodgkin lymphoma.

  2016cited by this paper
• Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

  2016cited by this paper
• Treatment of advanced-stage Hodgkin lymphoma.

  2016influential reference
• Treatment of relapsed and refractory Hodgkin Lymphoma.

  2016cited by this paper
• PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

  2016cited by this paper
• Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

  2012cited by this paper
• Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

  2012cited by this paper
• Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

  2012cited by this paper
• How I treat relapsed and refractory Hodgkin lymphoma.

  2011cited by this paper
• The biology of Hodgkin's lymphoma

  2009cited by this paper
• Standard therapy of advanced Hodgkin lymphoma.

  2009cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper

• Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.

  2026cites this paper
• Cellular and Novel Immunotherapies for Classic Hodgkin Lymphoma.

  2026cites this paper
• Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions

  2026influential citation
• Trends in Survival for Classical Hodgkin Lymphoma (cHL) in the Modern Treatment Era: A SEER Population Study

  2026cites this paper
• Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma.

  2026cites this paper
• The role of immune checkpoint molecules in cancers

  2026cites this paper
• Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.

  2026cites this paper
• Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

  2026cites this paper
• Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma.

  2025cites this paper
• Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics

  2025cites this paper
• Successful Pregnancy Outcome in a Patient Treated with Pembrolizumab and Exposed to Fluoro-Deoxyglucose (18F-FDG) PET/CT: Case Report and Review of Literature

  2025cites this paper
• PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma

  2025cites this paper
• Clinicopathological Study of Hodgkin Lymphoma in Relation to Programmed Death-Ligand 1 (PD-L1) Expression and Epstein-Barr Virus (EBV) Status

  2025cites this paper
• Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas

  2025cites this paper
• Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma.

  2025cites this paper
• Natural killer cell engagers for cancer immunotherapy

  2025cites this paper
• Can Pembrolizumab or Nivolumab be efficiently used against colorectal cancers with defective mismatch repair and high index of microsatellite instability?

  2025cites this paper
• Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

  2025cites this paper
• Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas

  2025cites this paper
• Characterization of cancer‐associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classic Hodgkin lymphoma

  2025cites this paper
• Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers

  2025cites this paper
• Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy.

  2025cites this paper
• Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine

  2025cites this paper
• Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

  2025cites this paper
• Peripheral EBV antigen-specific T cell is dysfunctional in Epstein–Barr virus positive diffuse large B-cell lymphoma

  2025cites this paper
• ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma.

  2025cites this paper
• Role of immune checkpoint inhibitors in breast cancer and hematological malignancies

  2025cites this paper
• Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine—A Systematic Review

  2025cites this paper
• Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma

  2025cites this paper
• Evaluation and preservation of fertility in patients with hematologic malignancies.

  2025cites this paper
• Advances in lymphoma biomarkers research based on proteomics technology (Review)

  2025influential citation
• Immune Checkpoint Molecule Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Expressed in Lymphoma Subtypes With and Without Epstein-Barr Virus.

  2025cites this paper
• Low-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis

  2025cites this paper
• The role of non-malignant B cells in malignant hematologic diseases

  2025cites this paper
• Tumoricidal potential of binary therapy in lymphoma: Role of DC-NK cross-talk and checkpoint inhibitors.

  2025cites this paper
• High‐dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited‐stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial

  2025cites this paper
• Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments

  2025cites this paper
• Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies

  2025cites this paper
• Improved therapies, incomplete data: late toxicity after modern classical Hodgkin Lymphoma radiotherapy

  2025cites this paper
• Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies

  2025cites this paper
• Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

  2025cites this paper
• Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis.

  2025cites this paper
• Impact of Hematopoietic Stem Cell Transplantation on PD-1 Blockade Efficacy in Relapsed/Refractory Hodgkin’s Lymphoma

  2025cites this paper
• Dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma enhances immune activation and induces apoptotic pathway

  2025cites this paper
• β-Arrestin 2 as a Prognostic Indicator and Immunomodulatory Factor in Multiple Myeloma

  2025cites this paper
• CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS.

  2025cites this paper
• Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.

  2024cites this paper
• Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies

  2024influential citation
• Improvement of assessment in surrogate endpoint and safety outcome of single-arm trials for anticancer drugs

  2024cites this paper
• Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin’s lymphoma

  2024cites this paper
• Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center

  2024cites this paper
• Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma

  2024cites this paper
• Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies

  2024cites this paper
• The roles of migrasomes in immunity, barriers, and diseases.

  2024cites this paper
• Genetic alteration of class I HLA in cutaneous T-cell lymphoma.

  2024cites this paper
• 3D histology reveals that immune response to pancreatic precancers is heterogeneous and depends on global pancreas structure

  2024cites this paper
• Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma.

  2024cites this paper
• At the Cutting Edge: Novel Agents in Hodgkin Lymphoma and the Evolving Role of Radiation Therapy.

  2024cites this paper
• Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions

  2024cites this paper
• New PET Tracers for Lymphoma.

  2024cites this paper
• PD-L1 and PD-1 in Immune Regulation and Their Implications in Blood Cancers

  2024cites this paper
• Treatment of Epstein-Barr Virus infection in immunocompromised patients.

  2024cites this paper
• Mapping the spatial dynamics of the CD4+ T cell spectrum in classical Hodgkin lymphoma.

  2024cites this paper
• Analysis by TeloView® Technology Predicts the Response of Hodgkin’s Lymphoma to First-Line ABVD Therapy

  2024cites this paper
• The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma

  2024cites this paper
• The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab

  2024cites this paper
• Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy – A case report and literature review

  2024cites this paper
• Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

  2024influential citation
• Emerging immunotherapies in the Hodgkin lymphoma armamentarium

  2024cites this paper
• Regulatory mechanisms of PD-1/PD-L1 in cancers

  2024cites this paper
• Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma

  2024cites this paper
• Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?

  2024cites this paper
• Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

  2024cites this paper
• Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma

  2024cites this paper
• Antitumor activity of α‐pinene in T‐cell tumors

  2024cites this paper
• Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

  2024cites this paper
• Oncology Drug Approvals Under Health Canada’s Notice of Compliance With Conditions Policy: A Retrospective Cohort Analysis

  2024cites this paper
• How Early Can Checkpoint Inhibitors Induce a Complete Metabolic Response in Chemorefractory Hodgkin Lymphoma?

  2024cites this paper
• Immunotherapy in the Management of Hodgkin Lymphoma: Time for Immunotherapy for All?

  2024cites this paper
• Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

  2024cites this paper
• Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies

  2024cites this paper
• When to use stem cell transplantation for classical Hodgkin lymphoma.

  2024cites this paper
• Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

  2024cites this paper
• Extracellular Vesicle miR-122-5p as a Prognostic Biomarker in Pediatric Classical Hodgkin Lymphoma

  2024cites this paper
• Prognosis of patients with Hodgkin lymphoma and indeterminate response to PD-1 inhibitor therapy: considerations for application of LYRIC criteria in real clinical practice

  2024cites this paper
• Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma

  2024cites this paper
• Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.

  2024cites this paper
• Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis

  2024cites this paper
• Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.

  2024cites this paper
• Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer.

  2023cites this paper
• Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases

  2023cites this paper
• Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

  2023cites this paper
• Efficacy and limitations of pembrolizumab for lung cancer and Hodgkin lymphoma

  2023cites this paper
• The unfolding story of dying tumor cells during cancer treatment

  2023cites this paper
• Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine

  2023cites this paper
• Advances in the treatment of Hodgkin's lymphoma (Review)

  2023cites this paper
• Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment

  2023cites this paper
• Advances in the treatment of Hodgkin lymphoma: Current and future approaches

  2023cites this paper
• Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment.

  2023cites this paper
• Immunotherapy for Hodgkin lymphoma: from monoclonal antibodies to chimeric antigen receptor T-cell therapy.

  2023cites this paper